Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease

Authors

  • B. Müller,

    Corresponding author
    1. Institute for clinical medicine, University of Bergen, Bergen, Norway
    • Department of Neurology, Haukeland University Hospital, Bergen, Norway
    Search for more papers by this author
  • J. Assmus,

    1. Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway
    Search for more papers by this author
  • J. P. Larsen,

    1. Institute for clinical medicine, University of Bergen, Bergen, Norway
    2. Department of Neurology, Stavanger University Hospital, Stavanger, Norway
    3. The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway
    Search for more papers by this author
  • K. Haugarvoll,

    1. Department of Neurology, Haukeland University Hospital, Bergen, Norway
    2. Institute for clinical medicine, University of Bergen, Bergen, Norway
    Search for more papers by this author
  • G. O. Skeie,

    1. Department of Neurology, Haukeland University Hospital, Bergen, Norway
    2. Institute for clinical medicine, University of Bergen, Bergen, Norway
    Search for more papers by this author
  • O.-B. Tysnes,

    1. Department of Neurology, Haukeland University Hospital, Bergen, Norway
    2. Institute for clinical medicine, University of Bergen, Bergen, Norway
    Search for more papers by this author
  • the ParkWest study group

    Search for more papers by this author
    • Details of the ParkWest study group are present in appendix.

B. Müller, Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway

Tel.: +47 55 97 5045

Fax: +47 55 97 51 64

e-mail: bernd.muller@helse-bergen.no

Abstract

Objectives

Autonomic symptoms are present in early stages of Parkinson's disease (PD), but evidence on how they are influenced by dopaminergic treatment remains unclear. The aim of this study was to investigate the impact of dopaminergic treatment on autonomic symptoms in early PD in a population-based cohort.

Methods

A total of 171 drug-naive patients with PD were investigated at diagnosis and 12 months later. Orthostatic blood pressure was measured, and autonomic symptoms were assessed by a preliminary version of the Movement Disorders Society-sponsored new version of the Unified Parkinson's Disease Rating Scale (range 0–4).

Results

In the 82% using dopaminergic treatment after 1 year, constipation and orthostatic blood pressure drop increased. There was a tendency towards increased orthostatic dizziness and urinary dysfunction. Dysphagia scores were reduced, and this was associated with higher levodopa-equivalent daily dose.

Conclusions

Dopaminergic treatment during the first year after initiation seems to have only a minor impact on autonomic symptoms in early PD. It may increase constipation and orthostatic dizziness, while dysphagia can improve. Autonomic symptoms remained mild after 1 year of dopaminergic treatment.

Ancillary